>>Signaling Pathways>> Microbiology & Virology>> Virus Protease>>STING agonist-1

STING agonist-1 (Synonyms: STING Agonist-1)

Catalog No.GC12943

STING 효능제-1(G10)은 신종 알파바이러스에 대한 항바이러스 활성을 유도하는 인간 특이적 STING 효능제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

STING agonist-1 Chemical Structure

Cas No.: 702662-50-8

Size 가격 재고 수량
5mg
US$81.00
재고 있음
10mg
US$122.00
재고 있음
50mg
US$509.00
재고 있음
100mg
US$945.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

STING agonist-1 (G10) is human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM[1].

G10 induces IFN/IRF3- but not NF-κB-dependent transcription in human fibroblasts[1].G10 is an indirect activator of human STING-dependent phenotypes[1].G10-mediated IRF3 activation and anti-Alphaviral activity occur independently of IPS-1/MAVS-dependent signaling[1].STING is required for G10-mediated IRF3 activation, gene expression, and anti-Alphaviral activity[1].G10 induces STING-dependent synthesis and secretion of bioactive interferon[1].G10 induces innate antiviral mRNA expression in primary human cells[1].

References:
[1]. Sali TM, et al. Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog. 2015 Dec 8;11(12):e1005324.

리뷰

Review for STING agonist-1

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for STING agonist-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.